Literature DB >> 19273584

Functional analysis of upstream common polymorphisms of the dopamine transporter gene.

Mikhil N Bamne1, Michael E Talkowski, Kodavali V Chowdari, Vishwajit L Nimgaonkar.   

Abstract

The human dopamine transporter (DAT, SLC6A3) has been extensively investigated because of its potential involvement in neuropsychiatric disorders. The core elements responsible for its transcription have been identified. A regulatory role for certain genomic variants upstream to the core promoter is known. Recently, other single-nucleotide polymorphisms (SNPs) have been identified in this region and are thought to be associated with schizophrenia and bipolar I disorder. Hence, we have investigated the impact of common SNPs in a 2.8-kilobase region flanking the core promoter region (-2.7 to +63 base pair) in the neuroblastoma cell line SH-SY5Y. Haplotypes generated by site-directed mutagenesis revealed varying impact of individual SNPs on promoter activity using dual luciferase assays. In silico analyses also predicted allele-specific binding of transcription factors for some of these SNPs. Though electrophoretic mobility shift assays indicated several factors that appeared to bind to specific sites within this region, allele-specific binding was not detected for any SNP apart from rs3756450. We have thus identified novel putative regulatory domains flanking the core promoter of DAT that merit further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273584      PMCID: PMC2930346          DOI: 10.1093/schbul/sbp005

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  26 in total

1.  A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs.

Authors:  D J Vandenbergh; A M Persico; G R Uhl
Journal:  Brain Res Mol Brain Res       Date:  1992-09

2.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells.

Authors:  N C Andrews; D V Faller
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

3.  Structure and organization of the gene encoding human dopamine transporter.

Authors:  T Kawarai; H Kawakami; Y Yamamura; S Nakamura
Journal:  Gene       Date:  1997-08-11       Impact factor: 3.688

4.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

Review 5.  Molecular characterization of the dopamine transporter.

Authors:  B Giros; M G Caron
Journal:  Trends Pharmacol Sci       Date:  1993-02       Impact factor: 14.819

Review 6.  Neurotransmitter transporters: recent progress.

Authors:  S G Amara; M J Kuhar
Journal:  Annu Rev Neurosci       Date:  1993       Impact factor: 12.449

Review 7.  The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission.

Authors:  A Napolitano; A M Cesura; M Da Prada
Journal:  J Neural Transm Suppl       Date:  1995

8.  Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene.

Authors:  Tiffany A Greenwood; John R Kelsoe
Journal:  Genomics       Date:  2003-11       Impact factor: 5.736

Review 9.  DAncing past the DAT at a DA synapse.

Authors:  Stephanie J Cragg; Margaret E Rice
Journal:  Trends Neurosci       Date:  2004-05       Impact factor: 13.837

10.  Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter.

Authors:  B Giros; S el Mestikawy; N Godinot; K Zheng; H Han; T Yang-Feng; M G Caron
Journal:  Mol Pharmacol       Date:  1992-09       Impact factor: 4.436

View more
  7 in total

1.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

2.  A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia.

Authors:  Feng-Ling Xu; Mei Ding; Xue Wu; Yong-Ping Liu; Xi Xia; Jun Yao; Bao-Jie Wang
Journal:  J Mol Neurosci       Date:  2019-08-22       Impact factor: 3.444

3.  Associations between catecholaminergic, GABAergic, and serotonergic genes and self-reported attentional function in oncology patients and their family caregivers.

Authors:  John D Merriman; Bradley E Aouizerat; Janine K Cataldo; Laura B Dunn; Kord Kober; Dale J Langford; Claudia West; Bruce A Cooper; Steven M Paul; Christine Miaskowski
Journal:  Eur J Oncol Nurs       Date:  2014-12-15       Impact factor: 2.398

4.  Fine-mapping reveals novel alternative splicing of the dopamine transporter.

Authors:  Michael E Talkowski; Kathleen L McCann; Michael Chen; Lora McClain; Mikhil Bamne; Joel Wood; Kodavali V Chowdari; Annie Watson; Konasale M Prasad; George Kirov; Lyudmilla Georgieva; Draga Toncheva; Hader Mansour; David A Lewis; Michael Owen; Michael O'Donovan; Panagiotis Papasaikas; Patrick Sullivan; Douglas Ruderfer; Jeffrey K Yao; Sherry Leonard; Pramod Thomas; Fabio Miyajima; John Quinn; A Javier Lopez; Vishwajit L Nimgaonkar
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-10-18       Impact factor: 3.568

5.  Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts.

Authors:  James L Kennedy; Nian Xiong; Jinlong Yu; Clement C Zai; Jennie G Pouget; Jie Li; Kefu Liu; Hong Qing; Tao Wang; Eden Martin; Deborah L Levy; Zhicheng Lin
Journal:  Schizophr Bull       Date:  2015-12-26       Impact factor: 9.306

6.  Genetic basis of delay discounting in frequent gamblers: examination of a priori candidates and exploration of a panel of dopamine-related loci.

Authors:  Joshua C Gray; James MacKillop
Journal:  Brain Behav       Date:  2014-10-16       Impact factor: 2.708

7.  Short-active photoperiod gestation induces psychiatry-relevant behavior in healthy mice but a resiliency to such effects are seen in mice with reduced dopamine transporter expression.

Authors:  Molly A Kwiatkowski; Zackary A Cope; Maria L Lavadia; Chuck J A van de Cappelle; Davide Dulcis; Jared W Young
Journal:  Sci Rep       Date:  2020-06-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.